Drug intelligence / Profile preview

BHVI2

Development stage: Phase 2
Administration: Ophthalmic

Overview

BHVI2 is an experimental pharmaceutical agent under investigation for the treatment of myopia. It has been evaluated at the clinical trial level, including in combination with low-dose atropine, but its precise mechanism of action and molecular target have not been publicly disclosed. The drug is referenced as a novel intervention in the context of emerging therapies for myopia control, which include antimuscarinic, dopaminergic, and anti-inflammatory agents. As of current knowledge, BHVI2 remains investigational and has not received regulatory approval for any indication.

Beyond the preview

Go deeper on BHVI2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHVI2.

Explore the full profile